Processa Pharmaceuticals, Inc. (PCSA)

Over the past six months, Processa Pharmaceuticals, Inc.'s stock price has been impacted by several events. A 1-for-25 reverse stock split was implemented in December 2025. Clinical updates on the Phase 2 study in metastatic breast cancer for NGC-Cap led to a significant stock price increase. The company's attendance at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, was followed by a stock price decrease. The stock price as of May 4, 2026, was $2.64 per share, representing a decline of 57.11% from May 5, 2025.

Processa Pharmaceuticals, Inc. has a low seasonality score, suggesting that demand for its products and services is not significantly impacted by seasonal variations. The demand for its pipeline products is driven by medical need rather than seasonal factors.

Processa Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing Next Generation Cancer drugs and advancing select non-oncology programs. The company aims to improve the safety and efficacy of existing FDA-approved oncology therapies by modifying their metabolism and/or distribution, with a mission to develop products for patients with unmet or underserved medical conditions. Its major product candidates include PCS6422 (NGC-Cap) for metastatic colorectal and breast cancer, PCS499 for ulcerative necrobiosis lipoidica (NL), and PCS12852 for diabetic gastroparesis.

Processa Pharmaceuticals, Inc. is headquartered in Vero Beach, Florida, United States.

In the past year, Processa Pharmaceuticals' reputation has been influenced by its clinical trial progress and strategic activities. Positive clinical updates on its Phase 2 study for NGC-Cap in metastatic breast cancer contributed positively to its reputation. Presentations at major conferences enhanced visibility and engagement. A binding term sheet granting Intact Therapeutics, Inc. an exclusive option to license PCS12852 for gastroparesis validated Processa's approach. The company also disclosed its evaluation of corporate cryptocurrency treasury strategies in August 2025.

Processa Pharmaceuticals, Inc. has a mixed ownership structure, including institutional, insider, and retail investors. Institutional owners hold approximately 1.61% to 2.09% of the company's stock. Insiders own approximately 4.07% of the company's stock, with James E. Besser being the largest individual shareholder. Retail investors hold a substantial portion, approximately 93.84%, of the company's stock.